SCHEMBL4076170

SCHEMBL4076170

CSC(C)(C)c1cc(N)n(-c2ccc(OCCOC3CCCCO3)cc2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
KDM4C Q9H3R0 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.34
CHEK1 O14757 1/20 0.34
LMNA P02545 2/20 0.34
TNK2 Q07912 2/20 0.31
MAPK13 O15264 1/20 0.31
MAPK9 P45984 1/20 0.31
MAPK12 P53778 1/20 0.31
MAPK11 Q15759 1/20 0.31
MAPK14 Q16539 1/20 0.31
KCNH2 Q12809 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
TP53 P04637 1/20 0.31
PKM P14618 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
DHFR P00374 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4078729 0.91 KDM4C (0.39) MEN1KMT2ANPC1RAB9AKDM4C
SCHEMBL4076105 0.81 KDM4C (0.41) MEN1KMT2ANPC1RAB9AKDM4C
SCHEMBL17687524 0.81 KDM4C (0.41) MEN1KMT2ANPC1RAB9AKDM4C
SCHEMBL4079759 0.80 KDM4C (0.40) MEN1KMT2ANPC1RAB9AKDM4C
SCHEMBL16280188 0.80 L3MBTL1 (0.42) MEN1KMT2ANPC1RAB9AKDM4C
SCHEMBL16280145 0.80 MEN1 (0.39) MEN1KMT2ANPC1RAB9AKDM4C
SCHEMBL4076188 0.79 KDM4C (0.42) MEN1KMT2ANPC1RAB9AKDM4C
SCHEMBL16278814 0.78 KDM4C (0.39) MEN1KMT2ANPC1RAB9AKDM4C
SCHEMBL16280146 0.77 NPC1 (0.39) MEN1KMT2ANPC1RAB9AKDM4C
SCHEMBL16284440 0.77 L3MBTL1 (0.38) MEN1KMT2ANPC1RAB9AKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076356-B2 Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors PFIZER INC. (US) 2011-12-13 US disclosed
US-20090239899-A1 Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors PFIZER INC. 2009-09-24 US disclosed
EP-1778686-B9 TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS PFIZER LTD (GB) 2009-07-08 EP disclosed
US-7511057-B2 Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors PFIZER INC. (US) 2009-03-31 US disclosed
EP-1778686-B1 TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS PFIZER LTD (GB) 2008-10-29 EP disclosed
US-20060035922-A1 Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors PFIZER INC. 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035922-A1 Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors MAPK1, MAPKAPK5, MAPKAPK3 MEN1 4865/4885KMT2A 4210/4885NPC1 1088/4885
US-20090239899-A1 Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors MAPK1, MAPKAPK5, MAPKAPK3 MEN1 4865/4885KMT2A 4285/4885NPC1 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.